Evidence map›Paper›PMID 41560815›Full record

ArticleMaterials today. Bio2026

A molecular engineered NIR-II fluorescence agent with enhanced radiative and non-radiative decay for precision prostate cancer bone metastasis theranostics.

Yan Chen, Kai Chen, Tian Gao, Mengyuan Cui, Chenxin Lu, Zonghao You, Qingming Shen, Pengfei Sun, Min Ji, Ming Chen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yan ChenState Key Laboratory of Digital Medical Engineering, School of Biological Science & Medical Engineering, Southeast University, Nanjing, 210096, China.
Kai ChenState Key Laboratory of Flexible Electronics &Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing, 210023, China.
Tian GaoSurgical Research Center, Institute of Urology, Southeast University Medical School, Nanjing, 210009, China.
Mengyuan CuiState Key Laboratory of Digital Medical Engineering, School of Biological Science & Medical Engineering, Southeast University, Nanjing, 210096, China.
Chenxin LuState Key Laboratory of Digital Medical Engineering, School of Biological Science & Medical Engineering, Southeast University, Nanjing, 210096, China.
Zonghao YouSurgical Research Center, Institute of Urology, Southeast University Medical School, Nanjing, 210009, China.
Qingming ShenState Key Laboratory of Flexible Electronics &Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing, 210023, China.
Pengfei SunState Key Laboratory of Flexible Electronics &Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing, 210023, China.
Min JiState Key Laboratory of Digital Medical Engineering, School of Biological Science & Medical Engineering, Southeast University, Nanjing, 210096, China.
Ming ChenSurgical Research Center, Institute of Urology, Southeast University Medical School, Nanjing, 210009, China.
Bin XuSurgical Research Center, Institute of Urology, Southeast University Medical School, Nanjing, 210009, China.
Quli FanState Key Laboratory of Flexible Electronics &Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing, 210023, China.
Fang YangState Key Laboratory of Digital Medical Engineering, School of Biological Science & Medical Engineering, Southeast University, Nanjing, 210096, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rational design of organic phototheranostic agents that combine diagnostic and therapeutic capabilities for cancer treatment remains challenging due to the inherent competition between radiative and non-radiative energy dissipation pathways. Herein, a novel molecule, TQP-TTPA, is strategically designed by incorporating a bulky electron donor and extended π-bridge, resulting in red-shifted absorption and emission in the second near-infrared window (NIR-II), along with prominent NIR-IIa emission (1300-1500 nm), a high NIR-II extinction coefficient, and enhanced NIR-IIa fluorescence brightness and photothermal conversion efficiency (43.8 %). These favorable properties are attributed to the strong donor-acceptor (D-A) interaction and enhanced intramolecular motion. Quantum chemical calculations provide insights into the excited-state energy dissipation mechanism and the role of intramolecular motion in modulating photophysical behavior. Furthermore, the femtosecond transient absorption (fs-TA) spectroscopy reveals that the performance enhancement originates from efficient intramolecular charge transfer (ICT) and promoted intramolecular motion by rational donor/π-bridge engineering. Based on these advantages, alendronate-functionalized TQP-TTPA nanoparticles (TQP-TTPA@ALD NPs) are developed for precise and high-resolution NIR-II fluorescence (FLI), photoacoustic (PAI), and phototherml (PTI) trimodal imaging-guided high-efficiency photothermal therapy (PTT) of prostate cancer bone metastases. This work offers a molecular-level design strategy for organic phototheranostics with tunable radiative/non-radiative decay balance, bridging fundamental photophysics and precision cancer theranostics.

Indexed as

D-A-D typed small moleculesFemtosecond transient absorption spectroscopyMolecular conformationPhototheranostic platformPhotothermal enhancement

Identifiers

PMID41560815
PMCPMC12813202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.